{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056041","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.002646+00:00","generated_at":"2026-06-15T19:54:41.990538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Record Q1 revenue of $62.8M, up 20% YoY; net loss narrows to $0.16/share","bullets":["Revenue $62.8M, +20% YoY (+23% constant currency); Biopharma/Pharma +19%, Animal Health +30%, Reproductive Medicine +13%.","Net loss attributable to common stockholders $7.6M ($0.16/share) vs $15.4M ($0.31) YoY; adjusted EBITDA $2.9M vs $2.0M.","Commercial cell and gene therapy revenue +28% YoY; supports 652 clinical trials (82 Phase 3) and 10 commercial therapies.","Cash and short-term investments $522.6M; FY 2023 revenue guidance reaffirmed at $270-290M.","New partnerships with Syneos Health (jan 2023), Inception Fertility (Mar 2023), and Boston IVF (Apr 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056041","json":"https://secwatch.observer/filing/0001104659-23-056041.json","markdown":"https://secwatch.observer/filing/0001104659-23-056041.md","text":"https://secwatch.observer/filing/0001104659-23-056041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923056041/0001104659-23-056041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923056041/tm2314749d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:54:41.990538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d0c2731f975176e7ad72690e4d5bee8abbfceac","claim":"Cryoport, Inc. reported the first quarter ended March 31, 2023 results: revenue $62.8 million.","evidence_excerpt":"We are pleased to report that we delivered record revenue of $62.8 million for the first quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923056041/0001104659-23-056041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$62.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}